Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
COVID-19 underscores historical precedent for fear-driven responses that disregard autonomy among persons with low income who are also persons of color.
AMA J Ethics. 2021;23(11):E840-846. doi:
10.1001/amajethics.2021.840.
Laurence B. McCullough, PhD, Frank A. Chervenak, MD, and John H. Coverdale, MD, MEd
The best interests of a pregnant psychotic patient can be served by determining her decision making capacity and using surrogate decision making if needed.
AMA J Ethics. 2016;18(3):209-214. doi:
10.1001/journalofethics.2016.18.3.ecas2-1603.
Transitions in relabeling personalized medicine as precision medicine, precision health, or wellness genomics reflect shifting the locus of responsibility for health from individuals to clinicians and in shifting focus from genetic risk to genetic enhancement.
AMA J Ethics. 2018;20(9):E881-890. doi:
10.1001/amajethics.2018.881.
In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy.
AMA J Ethics. 2018;20(11):E1082-1093. doi:
10.1001/amajethics.2018.1082.
Jane Bartels, MBBS and Christopher J. Ryan, MBBS, MHL
When patients cannot give informed consent or refusal for antipsychotic medication, physicians must meet specific criteria to justify temporarily withholding a diagnosis.
AMA J Ethics. 2018;20(12):E1119-1125. doi:
10.1001/amajethics.2018.1119.